ABSTRACT
Introduction We document our data on the course of the coronavirus disease 2019 (COVID-19) infection in cancer patients in an attempt to help optimize their management in India and globally. Material and Methods Between February 2020 and January 2021, participating oncologists from Pune (members of the Oncology Group of Pune) documented effect of COVID-19 infection in their cancer patients. Binomial logistic regression analysis as well as correlation analysis was done using Pearson Chi-square test to determine significance of clinical factors. Results A total of 29 oncologists from 20 hospitals contributed their data involving 147 cancer patients who developed COVID-19 infections. COVID-19 infection resulted in higher deaths (likelihood ratio of 4.4) amongst patients with hematological malignancies (12/44 = 27.2%) as compared with those with solid tumors (13/90 = 14.4%, p = 0.030). Patients with uncontrolled or progressive cancer (11/34 = 32.4%) when they got infected with COVID-19 had higher mortality as compared with patients whose cancer was under control (14/113 = 12.4%; p = 0.020). Complication of thromboembolic episodes (seen in eight patients; 5.4% cases) was associated with higher risk (25.6 times) of death (five-eighths; 62.5%) as compared with those who did not develop it (20/139;14.4%; p <0.001). Discussion Patients with cancer should be advised to take strict precautions to reduce the risk of being infected with COVID-19. They should also be given priority for COVID-19 vaccination. If infected with COVID-19, patients with hematological malignancy and uncontrolled cancer are at higher risk of morbidity and mortality. When they are being treated (OPD or inpatient basis), additional precautions are necessary to ensure their exposure to potential COVID-19 virus is minimized. If they get infected with COVID-19, they should be given aggressive treatment to prevent complications, especially thromboembolic episodes. If they develop any thromboembolic complication, their risk of dying are significantly higher, and management should be modified accordingly.
ABSTRACT
Context: Population-based seroepidemiological studies are recommended to measure the extent of spread of coronavirus disease of 2019 (COVID-19) infection in an area. The present seroprevalence survey was planned with the aim to estimate the cumulative burden of the COVID-19 disease in the Pimpri Chinchwad corporation area. Aims: To estimate the cumulative burden of the COVID-19 disease in the Pimpri Chinchwad corporation area. Settings and Design: The study was carried out in Pimpri Chinchwad Municipal Corporation (PCMC) city area. It was a descriptive cross-sectional survey. Materials and Methods: A population-based seroprevalence study for immunoglobulin G (IgG) antibodies for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was carried out among 10082 residents in the age group of 6 years and above selected by cluster random sampling. Thirty-five clusters were in slums, 45 clusters in tenements and 120 clusters from housing societies. The fieldwork for the collection of samples was carried out from 16 June to 17 June 2021. For antibody testing, a kit from Abbott (SARS-CoV-2 IgG) was used which employs chemiluminescent microparticle immunoassay (CMIA) technology. Statistical Analysis Used: Frequency analysis was done for sociodemographic variables, the cumulative incidence of COVID-19, age-stratified infection rate, risk factors and COVID symptomatic versus asymptomatic cases. Chi-square test of association was applied to test the association between seropositivity and sociodemographic and clinical profile of participants. Results: The overall seropositivity for IgG antibodies was 81.34%. Those living in the Gaothan area (tenements) had a positivity rate of 84.5%. The age group between 45 and 60 years had a seropositivity of 91%. Conclusions: The study indicates that a considerable proportion of the population had encountered the novel coronavirus approaching herd immunity.